Suppr超能文献

局灶节段性肾小球硬化症疾病逆转的机制

Mechanisms of disease reversal in focal and segmental glomerulosclerosis.

作者信息

Yang Hai-Chun, Fogo Agnes B

机构信息

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.

出版信息

Adv Chronic Kidney Dis. 2014 Sep;21(5):442-7. doi: 10.1053/j.ackd.2014.04.001.

Abstract

It is well known that progression of chronic kidney disease can be ameliorated or stabilized by different interventions, but more studies indicate that it can even be reversed. Most data suggest that current therapy, especially renin-angiotensin system inhibition alone, is not sufficient to initiate and maintain long-term regression of glomerular structural injury. In this article, we review the potential reversal of glomerulosclerosis and evidence from both human and animal studies. We discuss mechanisms that involve matrix remodeling, capillary reorganization, and podocyte reconstitution. In the future, a multipronged strategy including novel anti-inflammatory and antifibrotic molecules should be considered to potentiate regression of glomerulosclerosis.

摘要

众所周知,慢性肾脏病的进展可通过不同干预措施得到改善或稳定,但更多研究表明其甚至可以逆转。大多数数据表明,当前的治疗方法,尤其是单独使用肾素-血管紧张素系统抑制剂,不足以启动并维持肾小球结构损伤的长期逆转。在本文中,我们回顾了肾小球硬化潜在的逆转情况以及来自人类和动物研究的证据。我们讨论了涉及基质重塑、毛细血管重组和足细胞重构的机制。未来,应考虑采用包括新型抗炎和抗纤维化分子在内的多管齐下策略,以增强肾小球硬化的逆转。

相似文献

1
Mechanisms of disease reversal in focal and segmental glomerulosclerosis.
Adv Chronic Kidney Dis. 2014 Sep;21(5):442-7. doi: 10.1053/j.ackd.2014.04.001.
3
ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation.
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):234-48. doi: 10.1177/1470320314543910. Epub 2014 Aug 20.
4
Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.
J Histochem Cytochem. 2019 Sep;67(9):623-632. doi: 10.1369/0022155419850170. Epub 2019 May 22.
6
Prevalence of CD44-positive glomerular parietal epithelial cells reflects podocyte injury in adriamycin nephropathy.
Nephron Exp Nephrol. 2013;124(3-4):11-8. doi: 10.1159/000357356. Epub 2014 Jan 8.
7
Compound effects of aging and experimental FSGS on glomerular epithelial cells.
Aging (Albany NY). 2017 Feb 17;9(2):524-546. doi: 10.18632/aging.101176.
8
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.
J Am Soc Nephrol. 2003 Nov;14(11):2833-42. doi: 10.1097/01.asn.0000095248.91994.d3.

引用本文的文献

1
Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy.
Front Immunol. 2024 Jan 15;14:1335936. doi: 10.3389/fimmu.2023.1335936. eCollection 2023.
2
Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.
Lab Invest. 2024 Feb;104(2):100305. doi: 10.1016/j.labinv.2023.100305. Epub 2023 Dec 17.
3
Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.
Kidney360. 2022 Apr 18;3(7):1169-1182. doi: 10.34067/KID.0001032022. eCollection 2022 Jul 28.
4
The Pathology Lesion Patterns of Podocytopathies: How and why?
Front Cell Dev Biol. 2022 Feb 24;10:838272. doi: 10.3389/fcell.2022.838272. eCollection 2022.
6
Alport Syndrome Classification and Management.
Kidney Med. 2020 Aug 7;2(5):639-649. doi: 10.1016/j.xkme.2020.05.014. eCollection 2020 Sep-Oct.
7
Emerging drugs for treatment of focal segmental glomerulosclerosis.
Expert Opin Emerg Drugs. 2020 Sep;25(3):367-375. doi: 10.1080/14728214.2020.1803276. Epub 2020 Aug 12.
8
Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.
J Histochem Cytochem. 2019 Sep;67(9):623-632. doi: 10.1369/0022155419850170. Epub 2019 May 22.
9
Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.
Physiol Genomics. 2018 Jan 1;50(1):20-34. doi: 10.1152/physiolgenomics.00039.2017. Epub 2017 Nov 10.
10
Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.
J Inherit Metab Dis. 2017 Sep;40(5):703-708. doi: 10.1007/s10545-017-0054-2. Epub 2017 Jun 13.

本文引用的文献

1
The regenerative potential of parietal epithelial cells in adult mice.
J Am Soc Nephrol. 2014 Apr;25(4):693-705. doi: 10.1681/ASN.2013050481. Epub 2014 Jan 9.
2
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9.
3
Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids.
J Am Soc Nephrol. 2014 Jan;25(1):92-104. doi: 10.1681/ASN.2012111101. Epub 2013 Sep 12.
4
Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease.
Am J Pathol. 2013 Aug;183(2):542-57. doi: 10.1016/j.ajpath.2013.04.024. Epub 2013 Jun 14.
5
Podocyte regeneration: who can become a podocyte?
Am J Pathol. 2013 Aug;183(2):333-5. doi: 10.1016/j.ajpath.2013.04.009. Epub 2013 May 29.
6
Glomerular parietal epithelial cells in kidney physiology, pathology, and repair.
Curr Opin Nephrol Hypertens. 2013 May;22(3):302-9. doi: 10.1097/MNH.0b013e32835fefd4.
7
Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS.
Am J Physiol Renal Physiol. 2013 Jun 1;304(11):F1375-89. doi: 10.1152/ajprenal.00020.2013. Epub 2013 Mar 13.
9
Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents.
Hypertension. 2013 Apr;61(4):901-7. doi: 10.1161/HYPERTENSIONAHA.111.00639. Epub 2013 Feb 25.
10
Chronic kidney disease following acute kidney injury-risk and outcomes.
Nat Rev Nephrol. 2013 Feb;9(2):77-85. doi: 10.1038/nrneph.2012.280. Epub 2012 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验